Shriya Goyal

[Vincent Rajkumar @VincentRK]

My 2026 Update on Diagnosis, Risk Stratification, and Treatment of Myeloma is out! #OpenAccess

It’s current including all recent advances in immunotherapy. Managed to squeeze in iberdomide approval from 6 days ago! Bookmark!

https://t.co/VUheu7xlMr

[Ronak H. Mistry, DO @rmistry91]

#ICYMI: the long-awaited updated @ASH_hematology #ITP guidelines are here!

With so many new agents for managing ITP, I’m excited for these recs to better help our patients achieve durable platelet responses and improved QOL

Link: https://t.co/QY57AsYnBE

[The Fellow On Call @TheFellowOnCall]

Surgery can play a key role in the mgmt of Head and Neck Cancer. So this week we welcome with Dr. Michael Topf @TopfHNS from @VanderbiltENT to talk surgical decision-making and management in HNC.

We talk complex decision-making, changes in the field, & so much more!

Link in bio

[Vincent Rajkumar @VincentRK]

For physicians who deal with lots of referrals on “abnormal free light chain ratio” incidental finding.

Our recommendation is unless the FLC ratio is <0.125 or >8 or unless you are worried about myeloma clinically, or dealing with biopsy proven AL amyloid or MIDD or PGNMID, ask referring physicians to repeat in 6 months and if stable consider it as possible LC-MGUS with subsequent testing only if symptoms concerning for myeloma, amyloid etc develop. Defer bone marrow biopsy or bone survey.

See algorithm below. @nejm
Note labs report K/L ratio. Not involved /uninvolved. For ease of use you can calculate involved (high value) / uninvolved (low value). And use 8 as cut off as shown in figure. Otherwise you have to follow one cutoff for lambda and one for kappa.

https://t.co/vxDm5hpoPx

[Vincent Rajkumar @VincentRK]

I would like to share the story of how a patient with cancer came up with the idea for a randomized trial, &amp; how listening to him saved a lot of lives.

1/ In 2002, I had just completed a randomized trial with the notorious drug thalidomide for the cancer, multiple myeloma.

[Shriya Goyal @ShriyaGoyal5]

@OncoThor It’s seems like a great opportunity! Thanks for sharing! Is this position available for 2027 or 2028 recruitment cycle?

[Prof. Rita Orji, PhD @ritapurity]

If you are a beginner researcher, this paper will help you.

[Tony Breu @tony_breu]

Why don't elephants get cancer?

Our latest episode is up on YouTube. Give it a look and prescribe for future episodes.

https://t.co/4pN1o17hj0

[CORE IM @COREIMpodcast]

🩸Need a refresher on all things iron deficiency?

Join one of our favorite hematologists, @acweyand, as she helps explain the nuances of iron deficiency!

https://t.co/OFpa2fGR4P

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

MSK researchers are applying findings from single-cell technology and computational tools toward understanding and treating metastasis. At #AACR24, @dana_peer discussed results from three studies on how cellular plasticity drives cancer metastasis. More: https://t.co/pWHuA9feSG

[AA&MDSIF @aamdsif]

Don't Miss this important webinar that features the latest research presented at the annual ASH meeting for MDS and AML - Myelodysplastic Syndromes and Acute Myeloid Leukemia.
April 11 at 10:00 AM Eastern Time(US)!

#MDS #acuteleukemia #myelodysplasia #ASH23

[Abhay Singh @CloneTracker]

Must listen!! Cancer and cardiovascular disease have so much in common, yet often, the cognitive distraction fails to acknowledge their interconnectedness!

[The Clinical Problem Solvers @CPSolvers]

Paging all incoming interns #MedTwitter!

Join us for our intern bootcamp tomorrow, April 2 at 1:30pm EST to learn to differentiate STEMI, NSTEMI, and other myocardial injuries!

You won't want to miss this ~vital~ review. Join for free here! https://t.co/7jq32u0wk4

[JAMA Oncology @JAMAOnc]

Most viewed in the last 7 days from @JAMAOnc:

Do patients with resectable NSCLC and tumor programmed cell death 1 ligand 1 levels less than 1% benefit from neoadjuvant chemoimmunotherapy?

https://t.co/yRuI5USEF7

[Shriya Goyal @ShriyaGoyal5]

@UGrewalMD @IowaMed @UIowaCancer @curecc Congratulations!

[LSU Health Shreveport Internal Medicine Residency @LSUHS_IM]

Congratulations to this incredible group of interns! We're so excited to have you join our program! #IMmatch #match2024

[Anuj Thakre @thakre_anuj]

Excited and eagerly looking forward to this opportunity!

@ShriyaGoyal5 @LSUHS_IM

[The Clinical Problem Solvers @CPSolvers]

#MedTwitter We're excited for our morning report with the LSU Health Shreveport Internal Medicine residency program tomorrow, March 9 at 12pm EST!

Join us for a fun case and to learn more about their residency program! https://t.co/7jq32u0wk4

[LSU Health Shreveport Internal Medicine Residency @LSUHS_IM]

So proud of this team 💪💪💪
Good luck @thakre_anuj and @ShriyaGoyal5

[JAMA Oncology @JAMAOnc]

The use of the VEGF inhibitors sorafenib, sunitinib, and pazopanib was associated a 2-fold increase in the risk of aortic aneurysm and aortic dissection in patients with cancer. https://t.co/2HyGVLJqEh